INTRON BIOTECHNOLOGY, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,100 KRW | +1.16% |
|
-0.33% | -30.52% |
| Sales 2022 | 14.01B 10.14M | Sales 2023 | 9.59B 6.94M | Capitalization | 291B 211M |
|---|---|---|---|---|---|
| Net income 2022 | 5.71B 4.14M | Net income 2023 | -9.7B -7.02M | EV / Sales 2022 | 13.8 x |
| Net cash position 2022 | 76.58B 55.44M | Net cash position 2023 | 56.78B 41.11M | EV / Sales 2023 | 24.5 x |
| P/E ratio 2022 |
-23,726
x | P/E ratio 2023 |
-30.1
x | Employees | 81 |
| Yield 2022 * |
-
| Yield 2023 |
1.14% | Free-Float | 81.28% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.16% | ||
| 1 week | -0.33% | ||
| 1 month | -12.48% | ||
| 3 months | -10.69% | ||
| 6 months | -24.88% | ||
| Current year | -30.52% |
1 week
5 940.00
6 160.00
1 month
5 940.007 040.00
Current year
5 940.009 300.00
1 year
5 250.0012 470.00
3 years
5 250.0027 150.00
5 years
5 250.0034 500.00
10 years
5 250.0046 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gyeong-Won Yoon
CEO | Chief Executive Officer | 52 | 01-12-02 |
Seong-Joon Yoon
CEO | Chief Executive Officer | 55 | 00-05-11 |
Jae-Goo Seol
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Sun Yang
BRD | Director/Board Member | 59 | - |
Seong-Joon Yoon
CEO | Chief Executive Officer | 55 | 00-05-11 |
Gyeong-Won Yoon
CEO | Chief Executive Officer | 52 | 01-12-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 6,100 | +1.16% | 85,799 |
| 24-05-30 | 6,030 | -0.66% | 64,240 |
| 24-05-29 | 6,070 | +1.34% | 84,974 |
| 24-05-28 | 5,990 | -0.17% | 128,124 |
| 24-05-27 | 6,000 | -1.96% | 196,840 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.52% | 146M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- A048530 Stock
